SUBSCRIBE
SUBSCRIBE

Sound Pharmaceuticals

IN THE PRESS
Press Releases
Sound Pharma to Present SPI-1005 Preclinical and Clinical Hearing Loss and Tinnitus Data at the Defense Health Agency Hearing Center of Excellence Symposia and ARO MWM
February 18, 2025
 · 
3 min read
Press Releases
Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005
December 10, 2024
 · 
5 min read
BioForest
Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA
May 20, 2024
 · 
3 min read
BioForest
Sound Pharma to present positive interim data from its Phase 2b Cystic Fibrosis STOP Ototoxicity Trial
January 30, 2024
 · 
2 min read
Drug Development
Sound Pharma completes enrollment in pivotal Phase 3 clinical trial of SPI-1005 for the treatment of Meniere’s disease involving hearing loss, tinnitus, and dizziness.
May 3, 2023
 · 
4 min read
Drug Development
Sound Pharma initiates enrollment in pivotal Phase 3 clinical trial of SPI-1005 for the treatment of hearing loss and tinnitus in Meniere’s disease
July 28, 2022
 · 
5 min read
BioForest
Sound Pharmaceuticals’ NIH Grant for a novel oral COVID-19 treatment increases to $4.2M
May 11, 2022
 · 
2 min read
Drug Development
Sound Pharmaceuticals awarded $3.1M NIH grant to test SPI-1005 in COVID-19
April 6, 2021
 · 
2 min read
Drug Development
FDA allows Sound Pharmaceuticals to test SPI-1005 as a novel treatment for COVID-19
August 31, 2020
 · 
2 min read
Drug Development
Sound Pharmaceuticals files IND to test SPI-1005 in Phase 2 COVID-19 trials
July 30, 2020
 · 
2 min read
Load More
JOBS